Endogenous antigens (prepared from the patient’s tumor) or exogenous antigens (known to be tumor-specific, for example, HER2 peptide) can be introduced with adjuvants into the patient to stimulate an effector and memory T cell response [63,64,65]. This evidence concerns the gene ERBB2 and neoplasm.